Market News / Story
Addex Therapeutics (APE) Spin-Out Completes NTX-253 Phase 1, Plans Phase 2
·
Addex Therapeutics said its 20%-owned spin-out Neurosterix completed Phase 1 studies of NTX-253 and plans to advance it into Phase 2 for schizophrenia. Material Details #DetailAI Analyst View1NTX-253 Phase 1 completedDe-risks safety/PK and enables Phase 2; increases asset value tied to Addex’s 20% stake.2Phase 2 development plannedNext catalyst track; patient efficacy readouts could be stock-moving.3Addex holds 20% of NeurosterixValue of Addex linked to spin-out…